Cytosolic NUAK1 Enhances ATP Production by Maintaining Proper Glycolysis and Mitochondrial Function in Cancer Cells.

NUAK1 cancer metabolism cell bioenergetic glycolytic switch mitochondrial donut oxidative cells seahorse assay

Journal

Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867

Informations de publication

Date de publication:
2020
Historique:
received: 01 04 2020
accepted: 04 06 2020
entrez: 6 8 2020
pubmed: 6 8 2020
medline: 6 8 2020
Statut: epublish

Résumé

NUAK1 is an AMPK-related kinase located in the cytosol and the nucleus, whose expression associates with tumor malignancy and poor patient prognosis in several cancers. Accordingly, NUAK1 was associated with metastasis because it promotes cell migration and invasion in different cancer cells. Besides, NUAK1 supports cancer cell survival under metabolic stress and maintains ATP levels in hepatocarcinoma cells, suggesting a role in energy metabolism in cancer. However, the underlying mechanism for this metabolic function, as well as its link to NUAK1 subcellular localization, is unclear. We demonstrated that cytosolic NUAK1 increases ATP levels, which associates with increased mitochondrial respiration, supporting that cytosolic NUAK1 is involved in mitochondrial function regulation in cancer cells. NUAK1 inhibition led to the formation of "donut-like" structures, providing evidence of NUAK1-dependent mitochondrial morphology regulation. Additionally, our results indicated that cytosolic NUAK1 increases the glycolytic capacity of cancer cells under mitochondrial inhibition. Nuclear NUAK1 seems to be involved in the metabolic switch to glycolysis. Altogether, our results suggest that cytosolic NUAK1 participates in mitochondrial ATP production and the maintenance of proper glycolysis in cancer cells. Our current studies support the role of NUAK1 in bioenergetics, mitochondrial homeostasis, glycolysis and metabolic capacities. They suggest different metabolic outcomes depending on its subcellular localization. The identified roles of NUAK1 in cancer metabolism provide a potential mechanism relevant for tumor progression and its association with poor patient prognosis in several cancers. Further studies could shed light on the molecular mechanisms involved in the identified metabolic NUAK1 functions.

Identifiants

pubmed: 32754444
doi: 10.3389/fonc.2020.01123
pmc: PMC7367139
doi:

Types de publication

Journal Article

Langues

eng

Pagination

1123

Informations de copyright

Copyright © 2020 Escalona, Muñoz, Pincheira, Elorza and Castro.

Références

Cell Death Dis. 2013 Jan 17;4:e461
pubmed: 23328668
Mol Carcinog. 2013 May;52(5):329-37
pubmed: 22228080
Am J Physiol Cell Physiol. 2007 Jan;292(1):C125-36
pubmed: 16971499
Cell Metab. 2019 Jul 2;30(1):201-211.e6
pubmed: 31056286
J Mol Endocrinol. 2013 Sep 10;51(2):R15-22
pubmed: 23873311
Oncogene. 2018 Feb 22;37(8):982-992
pubmed: 29106388
Nat Methods. 2012 Jun 28;9(7):676-82
pubmed: 22743772
Sci Rep. 2019 Sep 24;9(1):13748
pubmed: 31551501
Am J Cancer Res. 2017 May 01;7(5):1016-1036
pubmed: 28560055
Oncogene. 2004 Sep 16;23(42):7067-75
pubmed: 15273717
Oncogene. 2003 Sep 18;22(40):6177-82
pubmed: 13679856
J Biol Chem. 2005 Sep 9;280(36):31557-63
pubmed: 16014625
J Biol Chem. 2003 Jan 3;278(1):48-53
pubmed: 12409306
Sci Rep. 2018 Jan 10;8(1):350
pubmed: 29321618
Cell Syst. 2018 Jul 25;7(1):49-62.e8
pubmed: 29960885
Adv Drug Deliv Rev. 2009 Nov 30;61(14):1234-49
pubmed: 19733603
Biomol Ther (Seoul). 2018 Jan 1;26(1):39-44
pubmed: 29212305
Biochem J. 2014 Jan 1;457(1):215-25
pubmed: 24171924
Eur J Cancer. 2013 Feb;49(3):752-63
pubmed: 23063350
J Cell Biochem. 2019 Sep;120(9):16088-16107
pubmed: 31090959
Cancer Discov. 2018 May;8(5):632-647
pubmed: 29500295
Cell Metab. 2018 May 01;27(5):1007-1025.e5
pubmed: 29657030
Exp Lung Res. 2013 Feb;39(1):9-17
pubmed: 23215946
Nat Cell Biol. 2008 May;10(5):611-8
pubmed: 18391940
Cell. 2006 Mar 24;124(6):1283-98
pubmed: 16564017
Proc Natl Acad Sci U S A. 2014 Jan 7;111(1):7-8
pubmed: 24367081
J Cancer Res Clin Oncol. 2012 Feb;138(2):247-54
pubmed: 22105900
Mol Cell. 2020 Mar 19;77(6):1322-1339.e11
pubmed: 32006464
Front Oncol. 2016 Oct 27;6:213
pubmed: 27833898
PLoS One. 2016 May 11;11(5):e0154576
pubmed: 27167619
J Exp Clin Cancer Res. 2004 Jun;23(2):263-8
pubmed: 15354411
Biochim Biophys Acta. 2011 Jun;1807(6):552-61
pubmed: 20955683
Am J Pathol. 2004 Mar;164(3):987-95
pubmed: 14982852
J Clin Invest. 1999 Aug;104(3):263-9
pubmed: 10430607
Nature. 2012 Mar 28;483(7391):608-12
pubmed: 22460906
Oncogene. 2011 Jun 30;30(26):2933-42
pubmed: 21317932
Carcinogenesis. 2006 May;27(5):925-35
pubmed: 16361271
Sci Signal. 2010 Mar 30;3(115):ra25
pubmed: 20354225
Exp Neurol. 2020 May;327:113218
pubmed: 32035071
J Biol Chem. 2012 May 11;287(20):16379-89
pubmed: 22418434
Tumour Biol. 2013 Jun;34(3):1913-8
pubmed: 23516026
Sci Adv. 2016 May 27;2(5):e1600200
pubmed: 27386546
Med Oncol. 2014 Jul;31(7):61
pubmed: 24943992
Biochem J. 2015 Aug 1;469(3):325-46
pubmed: 26205489

Auteurs

Emilia Escalona (E)

Signal Transduction and Cancer Laboratory, Biochemistry and Molecular Biology Department, Faculty of Biological Sciences, Universidad de Concepción, Concepción, Chile.

Marcelo Muñoz (M)

Mitochondrial Medicine Laboratory, Institute of Biomedical Sciences, Faculty of Medicine and Faculty of Life Sciences, Universidad Andres Bello, Santiago, Chile.

Roxana Pincheira (R)

Signal Transduction and Cancer Laboratory, Biochemistry and Molecular Biology Department, Faculty of Biological Sciences, Universidad de Concepción, Concepción, Chile.

Álvaro A Elorza (ÁA)

Mitochondrial Medicine Laboratory, Institute of Biomedical Sciences, Faculty of Medicine and Faculty of Life Sciences, Universidad Andres Bello, Santiago, Chile.

Ariel F Castro (AF)

Signal Transduction and Cancer Laboratory, Biochemistry and Molecular Biology Department, Faculty of Biological Sciences, Universidad de Concepción, Concepción, Chile.

Classifications MeSH